NCT06978062 (NeoBEMA) is a Phase 1 clinical trial of Bemarituzumab in GastroEsophageal Cancer, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

Who is sponsoring NCT06978062?

NCT06978062 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

What drugs are being tested in NCT06978062?

Interventions in NCT06978062: Bemarituzumab, FLOT.

What condition does NCT06978062 study?

NCT06978062 studies GastroEsophageal Cancer.

Is NCT06978062 still recruiting?

NCT06978062 is currently not yet recruiting. Last updated 5 June 2025.

Last reviewed 2025-06-05 · How we verify

NCT06978062: NeoBEMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

Not yet recruiting Phase 1 Last updated 5 June 2025

What this trial tests

Phase 1 trial testing Bemarituzumab in GastroEsophageal Cancer in 27 participants. Not yet recruiting.

Timeline

20 February 2026

Primary endpoint
11 September 2028

28 September 2029

Quick facts

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	20 February 2026
Primary completion	11 September 2028
Estimated completion	28 September 2029

Drugs / interventions tested

Bemarituzumab — full drug profile →
FLOT — full drug profile →

Conditions studied

GastroEsophageal Cancer — all drugs for GastroEsophageal Cancer →

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC — full company profile →

Who can join

18 and older, any sex, with GastroEsophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label,multi-centre, phase 1b safety and feasibility study aiming to assess the safey and feasibility of bemarituzumab plus chemiotherapy (FLOT) for the peri-operative treatment of resectable gastroesophageal cancer. Following this neo-adjuvant part, patients should undergo surgery. Following surgery, patients will receive FLOT chemotherapy in combination with bemarituzumab. Imaging will be performed every 3 months for the first 2 years and thereafter every 6 months as per standard of care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bemarituzumab

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07146919 — AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer · Phase 1, PHASE2 · not yet recruiting
NCT05325866 — A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression · Phase 1, PHASE2 · completed
NCT05322577 — A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated A · Phase 1, PHASE2 · active not recruiting
NCT05267470 — A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpressio · Phase 1 · terminated

Other recruiting trials for GastroEsophageal Cancer

Currently open trials in the same condition.

NCT06906887 — PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer · Phase 2 · recruiting
NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06243757 — A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroeso · active not recruiting
NCT06138223 — The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES) · NA · recruiting

Other European Organisation for Research and Treatment of Cancer - EORTC trials

Trials by the same sponsor.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT06809322 — Vorasidenib Maintenance for IDH Mutant Astrocytoma · Phase 3 · recruiting
NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting
NCT05815927 — Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06978062 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Organisation for Research and Treatment of Cancer - EORTC
Last refreshed: 5 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06978062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing